**Immunosuppressive Compounds Exhibit Particular Effects on Functional Properties of Human Anti-Aspergillus TH1 Cells**

Lars Tramsen,a Stanislaw Schmidt,a Frauke Roeger,a Ralf Schubert,b Emilia Salzmann-Manrique,a Jean-Paul Latgé,c Thomas Klingebiel,a Thomas Lehnbecherb

Pediatric Hematology and Oncologya and Pediatric Allergy, Pneumology, and Cystic Fibrosis,b Children's Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany; Institut Pasteur, Paris, Francec

Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at high risk for invasive aspergillosis. Whereas adoptive immunotherapy transferring donor-derived anti-Aspergillus TH1 cells has been shown to be beneficial for HSCT recipients suffering from invasive aspergillosis, little is known about the impact of commonly used immunosuppressants on the functional properties of anti-Aspergillus TH1 cells. Anti-Aspergillus TH1 cells were coincubated with different concentrations of methylprednisolone, cyclosporine (CsA), mycophenolic acid (MPA), the active component of mycophenolate mofetil, and rapamycin. Immunosuppressants were tested in concentrations reflecting common target levels in serum and in significantly lower and higher concentrations. Apoptosis of anti-Aspergillus TH1 cells, as well as proliferation and production of gamma interferon (IFN-γ) and CD154 upon restimulation, was evaluated in the presence and absence of immunosuppressive compounds. All dosages of CsA, MPA, and methylprednisolone significantly decreased the number of viable anti-Aspergillus TH1 cells in the cell culture, which was due partly to an impaired proliferative capacity of the cells and partly to an increased rate of apoptosis. In addition, CsA significantly decreased the number of IFN-γ-producing cells and had the highest impact of all immunosuppressants on IFN-γ levels in the supernatant. CsA also significantly decreased the expression of CD154 by anti-Aspergillus TH1 cells. Variant dosages of immunosuppressants exhibit particular effects on essential functional properties of anti-Aspergillus TH1 cells. Our findings may have an important impact on the design of clinical trials evaluating the therapeutic benefit of anti-Aspergillus TH1 cells in allogeneic HSCT recipients suffering from invasive aspergillosis.

Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at high risk for invasive fungal disease, in particular, for invasive aspergillosis (1–3). Despite the availability of new antifungal compounds, the mortality rate for invasive aspergillosis reaches up to 70% in this patient population (4, 5). While severe and prolonged neutropenia is the single most important risk factor for invasive aspergillosis, it has become clear that also adaptive immunity, in particular, the T helper (TH) cell population, plays a critical role in the host response to Aspergillus (6). In this regard, the majority of invasive aspergillosis occurs in HSCT recipients at a time when neutropenia has generally resolved but adaptive immune responses are still hampered (4, 7). Since the presence of TH1 lymphocytes correlates with a favorable outcome of invasive aspergillosis (8), it was speculated that adoptive transfer of donor-derived anti-Aspergillus TH1 cells to HSCT recipients will improve the prognosis of the infection. In fact, a small study of 10 allogeneic transplant recipients suffering from invasive aspergillosis demonstrated that the adoptive transfer of specific in vitro-generated anti-Aspergillus TH1 cells resulted in a clinical benefit (9); 9 out of the 10 patients who had received anti-Aspergillus TH1 cells cleared the infection and survived, whereas 6 out of 13 patients not receiving immunotherapy died due to invasive aspergillosis. Unfortunately, allogeneic HSCT recipients often require immunosuppressive agents as prophylaxis or treatment of graft-versus-host disease (GVHD). These compounds further increase the risk for invasive fungal disease, since they may have multiple negative effects on different arms of the immune system. For example, glucocorticosteroids not only suppress the phagocytic function of monocytes and neutrophils but also may impair antigen presentation, T cell function, and the expression of proinflammatory cytokines (10). However, data on the effect of various dosages of immunosuppressive compounds on the functional properties of anti-Aspergillus TH1 cells are lacking, which, in turn, has an important impact on the adoptive immunotherapeutic approach of using anti-Aspergillus TH1 cells. We therefore assessed the effect of commonly used immunosuppressive agents on important functional properties of anti-Aspergillus TH1 cells, such as proliferation and cytokine secretion.

(Most of this work was presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy [ICAAC], Denver, CO, 10 to 13 September 2013.)

**MATERIALS AND METHODS**

**Study subjects.** A total of 200 ml peripheral blood obtained from healthy volunteers (n = 8) was used for the generation of anti-Aspergillus TH1 cells. None of the individuals had a history of invasive fungal infection or had received any medication within 4 weeks of the blood draw. The protocol was approved by the local ethics committee.

**Fungal antigens.** The water-soluble cellular extract of Aspergillus fumigatus (strain CBS 144-89) was prepared as described before and stored.
in aliquots at −80°C (11). The extract was tested for sterility and endotoxin
toxin concentration.

**Immunosuppressive compounds.** The immunosuppressive compound
cyclosporine (CsA; Novartis Pharma, Nuremberg, Germany),
methyprednisolone (Sanoft Aventis, Frankfurt, Germany), mycophenolic
cid (MPA; Sigma-Aldrich, Steinheim, Germany), the active compo-
nent of mycophenolate mofetil (MMF), and rapamycin (Pfizer, New
York, NY, USA) were obtained commercially. All agents were stored and
dissolved according to the manufacturers’ instructions. At least three
concentrations were tested for each compound. In addition to testing the
concentrations reflecting common target levels in serum (e.g., 0.1 to 0.15
μg/ml for CsA, 1 to 3.5 μg/ml for MPA, and 0.001 to 0.02 μg/ml for
rapamycin) or concentrations based on pharmacokinetic data and com-
mune dose recommendations (e.g., 2 mg of methylprednisolone/kg of
body weight/day) (12–15), we evaluated each compound in significantly
lower and higher concentrations. Specifically, MPA was used at concen-
trations of 0.5, 5.0, and 50 μg/ml; methylprednisolone at 0.025, 0.25,
and 2.5 μg/ml; rapamycin at 0.001, 0.01, and 0.1 μg/ml, and CsA at 0.000015,
0.00015, 0.005, 0.015, 0.03, 0.15, and 0.75 μg/ml.

**Generation of anti-Aspergillus TH1 cells.** Anti-Aspergillus T cells
were enriched and cultivated as previously described, with some modifica-
tions (16). Briefly, peripheral blood mononuclear cells (PBMCs) were
isolated by means of Ficoll-Paque density gradient centrifugation, incubated
for up to 16 h with antigens of A. fumigatus (7.5 μg/ml), and co-cultured with
mononuclear cells (Mabs) against CD40 (Miltenyi Biotech, Bergisch-
Gladbach, Germany). Then, activated CD4+ T cells were isolated
using the CD154 MicroBead kit (Miltenyi Biotech), followed by a cultiva-
tion period of up to 14 days using cytotoxic T lymphocyte (CTL) medium
containing RPMI 1640, 100 IU/ml penicillin G, 100 mg/ml streptomycin
(Life Technologies, Darmstadt, Germany), and 10% pooled heat-inacti-
vated human serum. Cells were cultivated in the presence of recombinant
human interleukin 2 (rhIL-2) (50 U/ml; Chiron, Ratingen, Germany)
and restimulated twice during the culturing period using irradiated auto-
able Aspergillus antigen-loaded antigen-presenting cells (APCs), which
were obtained from PBMCs by the adherence method as described previ-
ously in detail (16). Cultivated cells were restimulated again for 2 h using
Aspergillus antigen-loaded APCs. Then, a second purification and expan-
sion step was performed by means of the gamma interferon (IFN-γ)
cytokine secretion assay (CSA; Miltenyi Biotech), followed by rapid expan-
sion for up to 7 days as previously described (16).

**Phenotypic and functional analyses of generated anti-Aspergillus
TH1 cells.** Generated cells were phenotypically characterized by means
of flow cytometry using Mabs against CD3, CD4, CD8, CD14, CD19, CD36,
CD69, human leukocyte antigen DR (HLA-DR), and 7-amino-actinomy-
cin D (7-AAD) and a FACSCanto II flow cytometer (BD Biosciences,
San Jose, CA, USA).

The viability of anti-Aspergillus TH1 cells was estimated by 7-AAD
staining and flow cytometry. Apoptosis and cell death were analyzed by
means of flow cytometry using annexin V and propidium iodide (PI)
staining (BD Biosciences) after 24 h of coincubation with and without the
immunosuppressive agent. Cell numbers were assessed using trypan blue
staining and flow cytometry. Apoptosis and cell death were analyzed by

**Assessment of cytokine concentration.** Cytokine levels were mea-
sured in the supernatant obtained on day 3 of the CFSE assay. Concentra-
tions were assessed by means of the cytometric bead array (CBA; BD
Biosciences) according to the manufacturer’s instructions. The lower level
of detection was 1.4 pg/ml for IL-4 and 0.8 pg/ml for IFN-γ.

**Statistical analyses.** Data were analyzed using GraphPad Prism (ver-
sion 5.04 for Windows; GraphPad Software, San Diego, CA, USA) and
compared with the paired t-test. A two-sided P of <0.05 was considered to
be statistically significant. Since the generation of Aspergillus-specific T
cells did not always result in a sufficient number of cells, the numbers of
experiments occasionally differed.

**RESULTS**

**Number and phenotypic characterization of generated anti-
Aspergillus TH1 cells.** For the generation of anti-Aspergillus TH1 cells,
a total number of 1.1 × 10⁸ PBMCs were stimulated with the antigen extract of A. fumigatus. In eight independent experiments, a final median number (range)
of 3.0 × 10⁶ (0.6 × 10⁶ to 6.0 × 10⁶) viable anti-Aspergillus T cells were received. Flow cytometry analysis revealed a highly purified homogenous CD3⁺ CD4⁺
(97.8% [range, 91.7 to 99.4%]), HLA-DR-expressing (>90%) T cell
population. Whereas only small numbers of CD3⁺ CD8⁺ T cells (<3%), CD3⁺ CD56⁺ NK cells (<1%), and CD3⁺ CD56⁺ NKT cells (<5%) were detected, no B cells or monocytes were
seen in the cell products (data not shown). Upon restimulation with antigen-loaded APCs, a significant percentage of CD3⁺ CD4⁺ T cells expressed the antigen-specific T helper cell activation
marker CD154 (median [range], 14.2% [3.3 to 31.2%]) and produced IFN-γ and TNF-α (medians [ranges], 9.45% [3.1 to
12.5%] and 16.8% [5.9 to 24.7%], respectively). Consistently,
concentrations of IFN-γ in the supernatant were highly elevated
(median [range], 2,001 pg/ml [475 to 2,663 pg/ml]), whereas IL-4 could not be detected, indicating that the generated cells were
activated TH1 cells.

CSA, methylprednisolone, and MPA result in a significantly
reduced number of anti-Aspergillus TH1 cells in the cell culture.
The efficacy of adoptively transferred anti-Aspergillus TH1 cells depends on the number of viable and functionally active effector
cells. After 6 days of culture, the number of viable anti-Aspergillus
TH1 cells was significantly lower when cells were coincubated with
methylprednisolone and MPA than when they were left untreated
controls (P < 0.05 in each case) (Fig. 1 and see Fig. S1 in the
supplemental material). Similarly, CSA at dosages of 0.03, 0.15,
and 0.75 μg/ml resulted in significantly lower numbers of viable
anti-Aspergillus TH1 cells than in the control (P < 0.05 each) (Fig.
1 and S1). Whereas CSA at a dosage of 0.0015 μg/ml decreased the
number of viable anti-Aspergillus TH1 cells in the culture by
approximately 50%, CSA at concentrations of 0.0005 μg/ml and
lower revealed no effect (Fig. S2). In contrast, none of the dosages
of rapamycin tested had a significant impact on the cell number
(Fig. 1).

Since reduced cell numbers in the culture may be the result of a
decreased proliferation and/or an increased rate of apoptosis, we

2650 iai.asm.org Infection and Immunity

Trammen et al.

Downloaded from http://iai.asm.org on August 15, 2017 by guest
evaluated both the proliferation and the apoptosis of anti-Aspergillus TH1 cells. Whereas approximately 90% of the anti-Aspergillus TH1 cells of the control cultivated in the absence of immunosuppressants underwent at least one cell cycle (median [range], 88% [46% to 98%]), methylprednisolone and MPA significantly reduced the proliferation of anti-Aspergillus TH1 cells ($P < 0.05$ in each case) (Fig. 2 and see Fig. S3 in the supplemental material). Notably, the strongest inhibition of proliferation was seen for MPA at dosages of 5 and 50 $\mu$g/ml. MPA did not significantly alter the rate of apoptosis of anti-Aspergillus TH1 cells, whereas apoptosis of the cells was increased by methylprednisolone; a statistically significant increase was seen for doses of 0.025 and 2.5 $\mu$g/ml ($P < 0.05$ in each case) (Fig. 3 and S4). Similarly, CSA dosages of 0.03 $\mu$g/ml and higher significantly decreased the proliferative response of anti-Aspergillus TH1 cells ($P < 0.05$ in each case) (Fig. 2), whereas CsA at concentrations of 0.0005 $\mu$g/ml and lower did not affect the proliferation (Fig. S5). CsA did not have a major impact on apoptosis (Fig. 3). In contrast to the other immunosuppressants evaluated, rapamycin did not significantly affect the proliferation and apoptosis of anti-Aspergillus TH1 cells (Fig. 2 and 3; see also Fig. S3 and S4). For all immunosuppressants tested, the effects on proliferation were similar when assessed at day 3 and at day 6 (data not shown).

CsA significantly decreases the percentage of IFN-γ-producing anti-Aspergillus TH1 cells and concentrations of IFN-γ in the supernatant. Since IFN-γ is an important molecule for the antifungal activity of anti-Aspergillus TH1 cells, we evaluated the impact of immunosuppressants on the percentage of IFN-γ-producing cells as well as on IFN-γ levels in the supernatant. Compared to no treatment, CsA at dosages of 0.03 $\mu$g/ml and higher significantly reduced both the percentage of IFN-γ-producing anti-Aspergillus TH1 cells and the IFN-γ levels ($P < 0.05$ in each case) (Fig. 4 and 5). Dilution experiments revealed that CsA at a dosage of 0.0005 $\mu$g/ml resulted in an inhibition of approximately 50% of IFN-γ production, whereas CsA at concentrations of 0.00015 $\mu$g/ml and lower did not affect IFN-γ production (see Fig. S6 in the supplemental material). Whereas none of the other immuno-

---

**FIG 1** Effects of various dosages of immunosuppressants on cell counts of cultivated anti-Aspergillus TH1 cells. Counts of viable anti-Aspergillus TH1 cells were assessed after 6 days of cultivation with or without (control) different dosages of immunosuppressants. Presented are percentages of viable anti-Aspergillus TH1 cells relative to cell counts for the untreated controls (100% [dashed line]). Depicted are medians (horizontal bars), interquartile ranges (boxes), and ranges (whiskers). Results are derived from eight independent experiments. *, $P < 0.05$.

**FIG 2** Effects of various dosages of immunosuppressants on the proliferation of anti-Aspergillus TH1 cells. Presented are percentages of proliferating anti-Aspergillus TH1 cells relative to cell counts for untreated controls (100%). Depicted are medians (horizontal bars), interquartile ranges (boxes), and ranges (whiskers). Results are derived from eight independent experiments. *, $P < 0.05$.

**FIG 3** Effects of various dosages of immunosuppressants on apoptosis of anti-Aspergillus TH1 cells. Presented are percentages of apoptotic anti-Aspergillus TH1 cells relative to cell counts for untreated controls (100%). Depicted are medians (horizontal bars), interquartile ranges (boxes), and ranges (whiskers). Results are derived from five independent experiments. *, $P < 0.05$.
suppressants tested significantly impacted the number of IFN-γ-producing cells (with the exception of the highest dosage of MPA) (Fig. 4), a significant decrease in the concentration of IFN-γ in the supernatant was detected for all dosages of methylprednisolone as well as for higher dosages of MPA and rapamycin (P < 0.05 in each case) (Fig. 5). However, this impact was considerably less pronounced than the effect by CsA. For all immunosuppressants tested, the effects on IFN-γ production were similar when assessed at day 3 and at day 6 (data not shown).

CsA negatively influences the expression of the antigen-specific activation marker CD154. Since CD154 is an important regulatory molecule in host immunity, we evaluated the impact of immunosuppressive compounds on this specific marker for antigen-activated T helper cells. At dosages of 0.03 μg/ml and higher, CsA significantly decreased the percentage of CD154-expressing T cells compared to the percentages in controls (P < 0.05 each) (Fig. 6 and see Fig. S7 in the supplemental material), whereas a decrease of approximately 50% of the CD154-expressing cells was seen at a dosage of 0.0005 μg/ml. CsA at dosages of 0.00015 μg/ml and lower did not have a relevant impact on CD154 expression (Fig. S8). A slight but significant increase in the percentage of CD154-expressing cells was seen for the highest dosages of MPA, whereas none of the other dosages of the immunosuppressants methylprednisolone and rapamycin tested affected the CD154 expression of anti-Aspergillus T_{17} cells (Fig. 6 and S7).

DISCUSSION

CsA, methylprednisolone, MMF, and rapamycin are commonly used immunosuppressants in the allogeneic HSCT setting for the prevention of graft rejection and the prophylaxis and treatment of GvHD. In the present study, we evaluated for the first time the effects of these immunosuppressants on important functional properties of specific anti-Aspergillus T_{17} cells. These analyses are important since the beneficial effects of adoptively transferred anti-Aspergillus T_{17} cells, which has been demonstrated in a pivotal clinical trial in HSCT recipients suffering from invasive aspergillosis (9), may be compromised or even abolished by the concomitant use of immunosuppressants. Our results demonstrate that

**FIG 4** Effects of various dosages of immunosuppressants on IFN-γ-producing anti-Aspergillus T_{17} cells. (Top) Percentages of IFN-γ-producing anti-Aspergillus T_{17} cell cells relative to cell counts for untreated controls (100%). Depicted are medians (horizontal bars), interquartile ranges (boxes), and ranges (whiskers). Results are derived from eight independent experiments. *, P < 0.05. (Bottom) Individual percentages of IFN-γ-producing anti-Aspergillus T_{17} cells in cells treated with different dosages of the immunosuppressants (right) and in untreated (control) cells without immunosuppressant (left). *, P < 0.05.
different dosages of the immunosuppressants tested have particular effects on cell proliferation and/or the upregulation of important effector molecules, such as IFN-γ and CD154 of anti-Aspergillus T11 cells (10). Although several previous studies have evaluated the influence of immunosuppressive compounds on lymphocytes, our studies are novel and important, since older studies either investigated bulk lymphocytes/PBMCs, which may exhibit functional properties different from those of antigen-specific T cells, or investigated CD8+ T cells specific for cytomegalovirus (CMV) or Epstein-Barr virus (EBV) stimulated with non-physiologic stimuli, such as ionomycin. It has also to be noted that the present, rather complex approach to generating Aspergillus-specific T cells was not designed for generating cells for a clinical trial (16, 17). Although the anti-Aspergillus T11 cells that result in a clinical benefit have been generated with a strategy different from that used for the anti-Aspergillus T11 cells in the present study (9), similar functional properties suggest that the cells used in the present study also exhibit a therapeutic effect.

CsA inhibits calcineurin, which is activated through T cell receptor signaling and leads to dephosphorylation of the nuclear factor of activated T cells (NFATc). Dephosphorylated NFATc is required for the transcription of several key genes for T cell activation, differentiation, and proliferation, such as the IFN-γ, TNF-α, or IL-2 gene (18). Therefore, it is not surprising that CsA at dosages higher than 0.0015 μg/ml significantly reduced the number of cultivated anti-Aspergillus T11 cells, which was caused mainly by the inhibition of proliferation. This observation is important, since the efficacy of adoptively transferred anti-Aspergillus T11 cells depends on the number of viable and functionally

FIG 5 Effects of various dosages of immunosuppressants on the levels of IFN-γ in the supernatant of anti-Aspergillus T11 cells. (Top) Percentage of the IFN-γ concentration in the supernatant relative to the IFN-γ level in the untreated control (100%). Depicted are medians (horizontal bars), interquartile ranges (boxes), and ranges (whiskers). Results are derived from eight independent experiments. *, P < 0.05. (Bottom) Individual levels of IFN-γ in the supernatant of anti-Aspergillus T11 cells treated with different dosages of the immunosuppressants (right) and in the supernatant of untreated (control) cells without immunosuppressant (left), *, P < 0.05.
active effector cells. Unfortunately, due to the low percentages of anti-Aspergillus TH1 cells in the peripheral blood of healthy individuals, clinical-scale isolation strategies result in a limited number of isolated anti-Aspergillus TH1 cells (19). On the other hand, in vitro data clearly demonstrate that the isolated anti-Aspergillus TH1 cells are not end differentiated and are able to proliferate when restimulated by a naturally processed antigen (19). This corroborates the in vivo observation for haploidentical transplant recipients in whom increasing numbers of anti-Aspergillus TH1 cells were found within 3 weeks of adoptive transfer of the donor-derived cells (9). Therefore, our data suggest that the concomitant use of CsA with adoptively transferred donor-derived anti-Aspergillus TH1 cells may result in an insufficient number of effector cells in vivo. In addition, our results show that CsA in subtherapeutic levels significantly inhibited the production of IFN-γ upon restimulation with naturally processed Aspergillus antigens, which is in line with recently reported data on purified memory CD4+ T cells stimulated with PMA and ionomycin (20), as well as with data on CMV-specific CD8+ T cells (21). This is an important observation, since IFN-γ is well known as one of the key molecules in the combat against Aspergillus (6). In clinical settings, it has been demonstrated that in patients with invasive aspergillosis, a predominant release of IFN-γ in culture supernatants upon stimulation with A. fumigatus antigens is associated with a favorable outcome (8). Our results also demonstrate that subtherapeutic levels of CsA significantly reduce the percentage of CD154-producing CD4+ T cells, which corroborates previous results on unspecific CD4+ T cells stimulated with PMA and ionomycin (22).

Notably, CD154, also known as CD40L, plays an important role in T cell-dependent B cell proliferation, memory cell formation, and B cell antibody response (23, 24). Our results suggest that CsA should be avoided, whenever possible, in patients receiving adoptive immunotherapy with anti-Aspergillus TH1.

MPA, the active component of MMF, is an inhibitor of the type II isoform of IMP dehydrogenase, which is involved in the synthesis of guanine nucleotides mandatory for cell proliferation (25). This corroborates our results demonstrating that MPA significantly reduced the number of cultivated anti-Aspergillus TH1 cells. In particular, MPA decreased proliferation at high dosages, whereas apoptosis was only slightly increased, and this increase did not reach statistical significance. A recent study reported on the negative impact of MPA on the proliferation of highly purified nonspecific CD4+ T cells stimulated by anti-CD3/anti-CD28 MAb (26), consistent with our results. In contrast, data on the effect of MPA on IFN-γ production are less clear. Corroborating our results with anti-Aspergillus TH1 cells, Abadja et al. observed a significant suppression of IFN-γ mRNA by MPA in CD4+ T cells stimulated by anti-CD3/anti-CD28 MAb (27). In contrast, Egli et al. (28) demonstrated only minor inhibition of IFN-γ production by CMV-specific T cells, and Heidt et al. (24) found highly varied results in IFN-γ mRNA expression without a significant impact of MPA on IFN-γ cytokine levels in the supernatant. However, due to the different study designs with different cell populations tested and different stimuli tested, the results of these studies are difficult to compare.

Glucocorticosteroids are widely used immunosuppressants in the prevention and treatment of GvHD, and they exhibit their potent immunosuppressive effects by a number of mechanisms, such as the suppression of the transcription of various proinflammatory genes, the promotion of apoptosis of T cells, and the strong inhibition of the proliferation of specific TH1 and TH2 clones (10, 29, 30). In line with this, we observed that methylprednisolone at dosages of 0.025 μg/ml and 2.5 μg/ml significantly increased both the rate of apoptosis and the rate of proliferation of anti-Aspergillus TH1 cells. In addition, as with our results, a negative effect of glucocorticosteroids on IFN-γ production was reported, which seems to be more pronounced for dexamethasone than for methylprednisolone (30, 31). Since methylprednisolone is recommended for the treatment of acute GvHD and used by the majority of centers as a first-line treatment, we chose this compound for our analysis (32, 33).

Rapamycin, an immunosuppressive macrolide, specifically inhibits its mammalian target of rapamycin complex 1 (mTORC1), which plays an important role in the differentiation and function of T cells and dendritic cells (DCs) (34). It was recently reported that rapamycin markedly reduced the proliferation of CD4+ T cells (35), in contrast to our results with anti-Aspergillus TH1 cells. However, this discrepancy may be explained by different dosages of rapamycin, since Battaglia et al. (35) observed this effect only when using rapamycin at a dosage of 1 μg/ml, a dosage 10- to 1,000-fold higher than the dosages that we used in our experiments. Similarly, others have reported only a weak inhibition of T cell activity with rapamycin concentrations lower than 0.1 μg/ml (36), which was the highest dose in our setting. Notably, we used in our experiments the recommended target range of rapamycin in allogeneic HSCT recipients, which is between 0.001 and 0.02 μg/ml (15). However, it is also important to note that rapamycin exhibits its immunosuppressive activity by a variety of mechanisms on different cell populations, such as the induction of proliferation of immunosuppressive CD4+ CD25+ FOXP3+ T regulatory cells or the
limitation of the proinflammatory capacity of mature DCs by downregulating IL-12 and upregulating IL-10 (34, 35).

In conclusion, we studied for the first time the effects of various commonly used immunosuppressants on important functional properties of anti-Aspergillus T\(_{H1}\) cells, such as proliferation and IFN-\(\gamma\) production, upon their restimulation with naturally processed antigens. Our \textit{in vitro} data demonstrate that CsA, MPA, and methylprednisolone exhibit significant and particular effects on these functional properties, whereas our data did not exhibit a major impact of rapamycin on the generated anti-Aspergillus T\(_{H1}\) cells. Although further studies are warranted to assess both newer immunosuppressants, such as anti-inflammatory antibodies, and the complex effects of immunosuppressants \textit{in vivo}, our data may have an important impact on the design of clinical studies evaluating the effect of adoptively transferred anti-Aspergillus T\(_{H1}\) cells to allogeneic HSC T cells suffering from invasive aspergillosis.

**ACKNOWLEDGMENT**

This work was supported by the Uniscientia Stiftung.

**REFERENCES**


